Vor Bio宣布1.5亿美元私募

2025-12-15 21:45

Vor Bio (NASDAQ:VOR) announced on Monday that it has entered into a securities purchase agreement to sell 13.87M shares of its common stock at a price of $10.81 per share in a private placement.
The company expects the gross proceeds to be approximately $150M and is expected to close on or about December 18, 2025.
The institutional investors, like RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital, and Venrock Healthcare Capital Partners, are participating in the financing, and Forbion is being granted the right to appoint one director to the company’s board of directors.
The company plans to use the net proceeds for advancement of the clinical development of telitacicept, including the ongoing global Phase 3 clinical trial for myasthenia gravis and Sjögren's disease, and for working capital and general corporate purposes.
Shares +3.13%.

More on Vor Biopharma